- Home
- BBIO vs LEN Comparison
BBIO vs LEN Comparison
Compare BBIO & LEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | LEN |
|---|---|---|
| Founded | 2015 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 18.8B |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | BBIO | LEN |
|---|---|---|
| Price | $65.53 | $82.07 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 25 | 15 |
| Target Price | $86.33 | ★ $97.23 |
| AVG Volume (30 Days) | 2.3M | ★ 3.8M |
| Earning Date | 05-12-2026 | 06-15-2026 |
| Dividend Yield | N/A | ★ 2.25% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.17 |
| Revenue | $502,076,000.00 | ★ $34,186,934,000.00 |
| Revenue This Year | $89.45 | N/A |
| Revenue Next Year | $73.78 | $4.41 |
| P/E Ratio | ★ N/A | $37.54 |
| Revenue Growth | ★ 126.26 | N/A |
| 52 Week Low | $50.68 | $75.70 |
| 52 Week High | $93.42 | $133.76 |
Technical Indicators
Market Signals| Indicator | BBIO | LEN |
|---|---|---|
| Relative Strength Index (RSI) | 28.95 | 50.22 |
| Support Level | $63.47 | $81.50 |
| Resistance Level | $70.49 | $89.39 |
| Average True Range (ATR) | 2.84 | 2.36 |
| MACD | -0.40 | 0.35 |
| Stochastic Oscillator | 7.18 | 85.66 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About LEN Lennar Corporation
Lennar is the second-largest public homebuilder in the United States, behind D.R. Horton, operating in 26 states. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.